Abstract: The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease.

Abstract: A method of taking a fluid samples from a processing line is provided that includes: placing an input conduit in fluid communication with the processing line; operatively coupling the input conduit to a peristaltic pump and a valve block; operatively coupling the valve block to a valve actuator so that the valves are movable among an off position, a flush position, and a sample position; controlling the valve actuator to move the valves to the flush position and turning on the peristaltic pump so that fluid from the processing line is pumped to a waste bag; and controlling the valve actuator to move a particular valve to the sample position and to move any valve upstream of the particular valve to the flush position while the peristaltic pump remains on so that fluid from the processing line is pumped to the sample bag associated with the particular valve.

Abstract: A sample collection device is provided. The collection device includes an input conduit, a plurality of automated sample collection bags, a waste collection bag, and a valve block. The input conduit is connectable to a fluid processing line. The automated sample collection bags each have a sample volume and the waste collection bag has a waste volume. The valve block a plurality of three-way valves and an output, where the plurality of three-way valves correspond in number to the plurality of automated sample collection bags, each of the three-way valves placing the input conduit in fluid communication with a different one of the plurality of sample collection bags. The output is in fluid communication with the waste collection bag. The collection device has a ratio of the waste volume to the sample volume of not more than 15:1.

Abstract: An automated sample collection workstation is provided. The workstation includes a processor, a peristaltic pump, a valve actuator, and an algorithm. The peristaltic pump and the valve actuator are in electrical communication with the processor. The valve actuator can move a plurality of valves, when disposed therein, among an off position, a flush position, and a sample position. The algorithm is resident on the processor and is configured to: move all of the valves to the off position and place the pump in an off state when no sampling or flushing is required, move all of the valves to the flush position and place the pump in an on state for a predetermined flush time period when flushing is required, and move a respective one of the valves to the sample position, move any of the valves upstream of the respective valve to the flush position, and place the pump to the on state for a predetermined sample time period when a sample is required.

Abstract: A liquid collection device is provided. The device includes an input conduit, an output conduit, a plurality of product collection containers, and a valve block. The input and output conduits are connectable to a liquid processing line. The valve block has a valve block input in fluid communication with the input conduit, a valve block output in fluid communication with the output conduit, and a plurality of valves. The valves correspond in number to product collection containers and each valve places the input conduit in liquid communication with a different one of the product collection containers. An automated liquid collection workstation for use with the liquid collection device and a method of automatically collecting liquid from a processing line or vessel are also provided.

Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin ? and rifaximin ? useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

Abstract: Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin ? and rifaximin ?, and a poorly crystalline form referred to as rifaximin ?, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.

Abstract: The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease.

Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin ? and rifaximin ? useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

Abstract: Object of the invention are mucoadhesive and controlled release formulations consisting of aqueous solutions containing 0.05% to 5% by weight of a natural purified polymer having xyloglucan structure and 10% to 70% by weight of glycerol. These formulations are suitable for the application on human mucous membranes, such as nasal, oral and vaginal mucous membranes, as moisturizing and softening agents or as pharmaceutical release system. Further objects of the invention are pharmaceutical formulations and medical devices suitable for the application to human mucous membranes, containing the mucoadhesive and controlled release formulations together with active ingredients and excipients.

Abstract: The present invention relates to Rifaximin polymorphic forms ?, ? and ?, to their use in medicinal preparations for the oral or topical route and to therapeutic methods using them.

Abstract: Polyols stabilize polymorphous form of rifaximin, in particular the ? form. When polyols having at least two hydroxy groups are added to rifaximin powder, polymorph ? is stable and remains stable in time independently from the environment humidity. In this invention a method to prepare formulations constituted by pure and stable polymorphous forms able to give a pharmaceutical product is described.

Abstract: The invention relates generally to pharmaceutical compositions comprising rifaximin effective at treating vaginal infections, and in particular bacterial vaginosis. The pharmaceutical compositions comprising rifaximin granules are characterized in that they release rifaximin in the vagina in a controlled way. The present invention also relates to processes for preparation of the rifaximin pharmaceutical compositions and their use in the treatment of vaginal infections. Effective dosages and courses of treatment useful and effective at recovering from the disease and preventing any possible relapse are also provided.

Abstract: The present invention describes rifaximin powder and to a process for preparing the same. The invention relates also to a pharmaceutical composition in solid form comprising said rifaximin, pharmaceutically acceptable excipients and optionally other ingredients. The compositions according to the invention are suitable for oral administration and are characterized by producing a controlled release of rifaximin, whereby a long-lasting effect is obtained in a patient.

Abstract: Disclosed are rifamycin derivatives having antibacterial activities, wherein the compounds have the following general formula: wherein: R is hydrogen or acetyl; R1 and R2 are independently selected from the group consisting of hydrogen, (C1-4)alkyl, benzyloxy, mono- and di-(C1-3)alkylamino-(C1-4)alkyl, (C1-3)alkoxy, (C1-4)alkyl, hydroxy-methyl, hydroxy-(C2-4)-alkyl, and nitro or R1 and R2 taken together with two consecutive carbon atoms of the pyridine nucleus form a benzene ring optionally substituted by one or two methyl or ethyl groups and R3 is hydroxyalkyl(C1-4). In addition, processes to obtain these compounds are described.

Abstract: Forms of rifaximin (INN) antibiotic, such as the poorly crystalline form named rifaximin ? are described, along with the production of medicinal preparations containing rifaximin for oral and topical use.

Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin ? and rifaximin ? useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.